应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02315 百奥赛图-B
休市中 10-10 16:08:08
25.080
-0.480
-1.88%
最高
25.520
最低
24.020
成交量
59.50万
今开
25.200
昨收
25.560
日振幅
5.87%
总市值
100.17亿
流通市值
27.78亿
总股本
3.99亿
成交额
1,483万
换手率
0.54%
流通股本
1.11亿
市净率
10.29
ROE
16.11%
每股收益
0.09
52周最高
31.340
52周最低
5.600
市盈率
272.82
股息
0.00
股息收益率
0.00
ROA
6.20%
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
百奥赛图-B盘中异动 早盘急速下跌5.09%报24.260港元
市场透视 · 02:12
百奥赛图-B盘中异动 早盘急速下跌5.09%报24.260港元
争夺“抗生素第一股”:“金主”携10亿入主,遭大股东狙击
市场资讯 · 10-04
争夺“抗生素第一股”:“金主”携10亿入主,遭大股东狙击
百奥赛图-B09月29日主力净流入130.2万元 散户资金抛售
市场透视 · 09-29
百奥赛图-B09月29日主力净流入130.2万元 散户资金抛售
港股异动 | 百奥赛图-B(02315)涨超5% 科创板IPO过会 近期连签默克、Tubulis等推进国际化合作
智通财经 · 09-25
港股异动 | 百奥赛图-B(02315)涨超5% 科创板IPO过会 近期连签默克、Tubulis等推进国际化合作
生物医药股盘初走高!荣昌生物涨近6%,药明巨诺-B涨超4%
老虎资讯综合 · 09-25
生物医药股盘初走高!荣昌生物涨近6%,药明巨诺-B涨超4%
百奥赛图-B(02315)建议A股发行获上交所科创板上市委员会批准
智通财经 · 09-24
百奥赛图-B(02315)建议A股发行获上交所科创板上市委员会批准
百奥赛图科创板过会!“模式动物三巨头”或将齐聚A股
大河财立方 · 09-24
百奥赛图科创板过会!“模式动物三巨头”或将齐聚A股
百奥赛图科创板IPO过会 从“实验小鼠”到布局全产业链
e公司 · 09-24
百奥赛图科创板IPO过会 从“实验小鼠”到布局全产业链
百奥赛图:从“千鼠万抗”到全球合作,中国Biotech的出海范本
新浪证券 · 09-23
百奥赛图:从“千鼠万抗”到全球合作,中国Biotech的出海范本
百奥赛图-B盘中异动 早盘股价大跌5.04%报26.020港元
市场透视 · 09-23
百奥赛图-B盘中异动 早盘股价大跌5.04%报26.020港元
H+A的百奥赛图募资的随意性与对科研人员卸磨杀驴来美化报表?
新浪财经 · 09-22
H+A的百奥赛图募资的随意性与对科研人员卸磨杀驴来美化报表?
百奥赛图“双业务线”持续放量:多项国际合作开启新阶段
新浪证券 · 09-22
百奥赛图“双业务线”持续放量:多项国际合作开启新阶段
百奥赛图IPO:一面是A+H“光辉”,一面是大量人员“优化”,扭亏为盈的背后,心酸的“研发耗材”
中金在线 · 09-22
百奥赛图IPO:一面是A+H“光辉”,一面是大量人员“优化”,扭亏为盈的背后,心酸的“研发耗材”
百奥赛图-B09月19日主力净流出0.7万元 散户资金买入
市场透视 · 09-19
百奥赛图-B09月19日主力净流出0.7万元 散户资金买入
百奥赛图合作伙伴IDEAYA举办十周年研发日,携手推进双抗ADC联合治疗新篇章
新浪证券 · 09-19
百奥赛图合作伙伴IDEAYA举办十周年研发日,携手推进双抗ADC联合治疗新篇章
基本面没变,港股混得不咋地的百奥赛图,能混好A股吗?尽管巨亏32.5亿以上,沈月雷2024年年薪42
中金在线 · 09-19
基本面没变,港股混得不咋地的百奥赛图,能混好A股吗?尽管巨亏32.5亿以上,沈月雷2024年年薪42
百奥赛图IPO:公司基本信息速览
览富财经网 · 09-19
百奥赛图IPO:公司基本信息速览
生物医药B类股午后拉升,百奥赛图涨超11%,润迈德涨超8%,加科思涨超5%
老虎资讯综合 · 09-18
生物医药B类股午后拉升,百奥赛图涨超11%,润迈德涨超8%,加科思涨超5%
百奥赛图(02315)技术平台频结硕果 连签默克、Tubulis等推进国际化合作
智通财经 · 09-18
百奥赛图(02315)技术平台频结硕果 连签默克、Tubulis等推进国际化合作
港股异动 | 百奥赛图涨超10%,科创版IPO即将接受审议,月初与默克达成抗体授权合作
智通财经 · 09-18
港股异动 | 百奥赛图涨超10%,科创版IPO即将接受审议,月初与默克达成抗体授权合作
加载更多
公司概况
公司名称:
百奥赛图-B
所属市场:
SEHK
上市日期:
2022-09-01
主营业务:
百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司通过五个分部开展业务。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动物。抗体开发分部利用抗体发现平台识别有可能成为候选药物的抗体。创新药开发分部研发创新药,专注肿瘤学和自身免疫性疾病治疗。
发行价格:
25.220
{"stockData":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"百奥赛图-B","latestPrice":25.08,"timestamp":1760083688890,"preClose":25.56,"halted":0,"volume":595000,"delay":0,"floatShares":110781920,"shares":399398420,"eps":0.09192865383986737,"marketStatus":"休市中","change":-0.48,"latestTime":"10-10 16:08:08","open":25.2,"high":25.52,"low":24.02,"amount":14828790,"amplitude":0.058685,"askPrice":25.08,"askSize":3000,"bidPrice":24.5,"bidSize":3500,"shortable":0,"etf":0,"ttmEps":0.36327602584817986,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1760319000000},"marketStatusCode":7,"adr":0,"listingDate":1661961600000,"exchange":"SEHK","adjPreClose":25.56,"openAndCloseTimeList":[[1760059800000,1760068800000],[1760072400000,1760083200000]],"volumeRatio":2.55145797478276,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02315","defaultTab":"news","newsList":[{"id":"2574145209","title":"百奥赛图-B盘中异动 早盘急速下跌5.09%报24.260港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574145209","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574145209?lang=zh_cn&edition=full","pubTime":"2025-10-10 10:12","pubTimestamp":1760062351,"startTime":"0","endTime":"0","summary":"2025年10月10日早盘10时12分,百奥赛图-B股票出现波动,股价急速跳水5.09%。截至发稿,该股报24.260港元/股,成交量15.1万股,换手率0.14%,振幅4.85%。资金方面,该股资金流入58.712万港元,流出260.206万港元。百奥赛图-B股票所在的生物技术行业中,整体涨幅为0.00%。百奥赛图-B公司简介:北京百奥赛图基因生物技术有限公司是一家主要从事药物开发业务及临床前研究中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101010123294c13772&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101010123294c13772&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2573934466","title":"争夺“抗生素第一股”:“金主”携10亿入主,遭大股东狙击","url":"https://stock-news.laohu8.com/highlight/detail?id=2573934466","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2573934466?lang=zh_cn&edition=full","pubTime":"2025-10-04 20:31","pubTimestamp":1759581060,"startTime":"0","endTime":"0","summary":"9月27日,广发证券发布关于盟科药业详式权益变动报告书的财务顾问核查意见。 然而,这份看似常规的核查意见背后,盟科药业第一大股东Genie Pharma已于9月24日公开征集表决权,明确表示将在10月9日的临时股东大会上对定增相关议案投反对票。 2022年8月5日,盟科药业在上交所科创板上市,成为“抗生素第一股”。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-10-04/doc-infsttpe4004363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","BK4554","ZM","BK4505","BK4585","LU1861559042.SGD","BK4525","BK4548","BK4023","688373","BK4532","BK0028","BK1161","02315","BK0201","600521","BK4613","BK0012","BK4588","BK0239","LU1861558580.USD","BK0185","BK4528","BK4551","BK4535","BK0188"],"gpt_icon":1},{"id":"2571399063","title":"百奥赛图-B09月29日主力净流入130.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2571399063","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571399063?lang=zh_cn&edition=full","pubTime":"2025-09-29 16:15","pubTimestamp":1759133735,"startTime":"0","endTime":"0","summary":"09月29日, 百奥赛图-B股价涨0.35%,报收28.70元,成交金额1446.0万元,换手率0.46%,振幅5.17%,量比0.90。百奥赛图-B今日主力资金净流入130.2万元,上一交易日主力净流出420.7万元。该股近5个交易日上涨4.38%,主力资金累计净流出213.1万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出5.2万元,其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929161828a6a5c67f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929161828a6a5c67f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2570055410","title":"港股异动 | 百奥赛图-B(02315)涨超5% 科创板IPO过会 近期连签默克、Tubulis等推进国际化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2570055410","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570055410?lang=zh_cn&edition=full","pubTime":"2025-09-25 10:21","pubTimestamp":1758766883,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B早盘涨超5%,截至发稿,涨4.87%,报29.26港元,成交额636.36万港元。消息面上,百奥赛图公布,上交所科创板上市委员会2025年第38次审议会议已于9月24日召开。根据会议审议结果,公司建议A股发行及于上交所科创板上市已获上交所科创板上市委员会批准。值得一提的是,百奥赛图近期宣布先后与德国Tubulis及全球领先的科技公司默克达成合作协议。Tubulis拟引进百奥赛图自主开发的全人抗体推进其ADC产品的研发和商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BJT1NW94.SGD","SG9999001176.SGD","IE0009355771.USD","SG9999014567.USD","LU2023250843.SGD","IE00BLSP4239.USD","LU1989771016.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00BLSP4452.SGD","LU1989772923.USD","LU0320765646.SGD","LU2324357040.USD","BK4559","HSCEI","SG9999013999.USD","YANG","LU2112291526.USD","SG9999001176.USD","SG9999002224.SGD","BK4007","SG9999015358.SGD","LU2361044865.SGD","LU0320765489.SGD","IE00BBT3K403.USD","LU2023250504.SGD","LU1035773651.USD","SG9999015341.SGD","LU0965508806.USD","LU1093756325.SGD","LU0238689110.USD","LU0965509010.AUD","LU1066051811.HKD","02315","LU0098860793.USD","LU1941712348.USD","LU1989772840.SGD","LU2089984988.USD","BK1161","159982","LU0965509283.SGD","BK4550","LU1093756168.USD","LU1917777945.USD","LU2361044949.HKD","LU2106854487.HKD","BK4588","MRK","LU1116320901.HKD"],"gpt_icon":0},{"id":"1143916555","title":"生物医药股盘初走高!荣昌生物涨近6%,药明巨诺-B涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143916555","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143916555?lang=zh_cn&edition=full","pubTime":"2025-09-25 09:38","pubTimestamp":1758764339,"startTime":"0","endTime":"0","summary":"$生物(000504)$医药股盘初走高,$荣昌生物(09995)$涨近6%,$药明巨诺-B(02126)$、$百奥赛图-B(02315)$涨超4%,$康方生物(09926)$、$康诺亚-B(02162)$涨超3%.","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"fd911261ff26421c117e7c83a448e782","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4614","02126","09995","02315"],"gpt_icon":0},{"id":"2569707801","title":"百奥赛图-B(02315)建议A股发行获上交所科创板上市委员会批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2569707801","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569707801?lang=zh_cn&edition=full","pubTime":"2025-09-24 21:43","pubTimestamp":1758721412,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百奥赛图-B(02315)公布,上交所科创板上市委员会2025年第38次审议会议已于 2025年9月24日召开。根据会议审议结果,公司建议A股发行及于上交所科创板上市已获上交所科创板上市委员会批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399300","159982","BK1161","02315"],"gpt_icon":0},{"id":"2570605073","title":"百奥赛图科创板过会!“模式动物三巨头”或将齐聚A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2570605073","media":"大河财立方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570605073?lang=zh_cn&edition=full","pubTime":"2025-09-24 20:47","pubTimestamp":1758718070,"startTime":"0","endTime":"0","summary":"业务方面,百奥赛图主要包括基因编辑、抗体开发、模式动物销售和临床前药效评价四大板块。百奥赛图称,已在2023年第三季度前基本完成该计划的主体工作。“模式动物三巨头”将齐聚A股,市场发展前景广阔除百奥赛图外,南模生物和药康生物也是国内模式动物市场的领先企业,三者并称为“模式动物三巨头”。百奥赛图此次成功过会,意味着这三家企业有望齐聚登陆A股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924204826a441257b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924204826a441257b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2570202050","title":"百奥赛图科创板IPO过会 从“实验小鼠”到布局全产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2570202050","media":"e公司","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570202050?lang=zh_cn&edition=full","pubTime":"2025-09-24 19:29","pubTimestamp":1758713340,"startTime":"0","endTime":"0","summary":"2022年9月登陆港股的百奥赛图(北京)医药科技股份有限公司即将回A,实现A+H上市。9月24日,上交所上市审核委员会召开2025年第38次上市审核委员会审议会议,审议百奥赛图首发事项,最终公司顺利过会。百奥赛图成立于2009年,是一家临床前CRO以及生物技术企业。依托于抗体药物发现平台的领先优势,百奥赛图通过RenMice小鼠授权以及“千鼠万抗”的形式展开抗体对外合作开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924193037a440ff5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924193037a440ff5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2569628796","title":"百奥赛图:从“千鼠万抗”到全球合作,中国Biotech的出海范本","url":"https://stock-news.laohu8.com/highlight/detail?id=2569628796","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569628796?lang=zh_cn&edition=full","pubTime":"2025-09-23 17:34","pubTimestamp":1758620040,"startTime":"0","endTime":"0","summary":"在抗体偶联药物热度持续攀升的当下,全球生物医药产业链迎来新一轮重塑。据弗若斯特沙利文预测,到2030年全球ADC外包服务市场规模将达到110亿美元,2022年至2030年的复合年增长率高达28.4%。 在这条高景气赛道上,国内Biotech正逐步走向全球舞台。百奥赛图便是其中的代表。随着海外合作不断拓展、抗体货架持续放量,公司正在成为中国Biotech出海的典型样本,也为全球新药研发提供了来自东方的创新引擎。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/enterprise/hk/2025-09-23/doc-infrnqyp7508791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","ADC","BK4231","02315","BK4080"],"gpt_icon":0},{"id":"2569261761","title":"百奥赛图-B盘中异动 早盘股价大跌5.04%报26.020港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2569261761","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569261761?lang=zh_cn&edition=full","pubTime":"2025-09-23 10:02","pubTimestamp":1758592967,"startTime":"0","endTime":"0","summary":"2025年09月23日早盘10时02分,百奥赛图-B股票出现异动,股价大幅跳水5.04%。截至发稿,该股报26.020港元/股,成交量4.4万股,换手率0.04%,振幅5.26%。百奥赛图-B股票所在的生物技术行业中,整体涨幅为0.29%。据悉,百奥赛图成立于2009年,是一家临床前CRO以及生物技术企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923100248a43d84f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923100248a43d84f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2569575343","title":"H+A的百奥赛图募资的随意性与对科研人员卸磨杀驴来美化报表?","url":"https://stock-news.laohu8.com/highlight/detail?id=2569575343","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569575343?lang=zh_cn&edition=full","pubTime":"2025-09-22 20:27","pubTimestamp":1758544070,"startTime":"0","endTime":"0","summary":"截至目前,百奥赛图在港股的市值约107亿港元,而这还是最近几个月涨上来的结果。03 费用调控“有妙招”,优化人员省大钱百奥赛图的费用变化堪称“神来之笔”。那些为项目付出心血的研发人员,转眼间就成了“卸磨杀驴”的对象。那么,百奥赛图给了这些被“优化”的员工多少补偿呢?百奥赛图的IPO之路,更像是一场精心计算的财务游戏:募资可以“随意砍”,盈利可以“优化”来,研发人员可以“耗材”化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092220404497a27012&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092220404497a27012&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2569075344","title":"百奥赛图“双业务线”持续放量:多项国际合作开启新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2569075344","media":"新浪证券","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569075344?lang=zh_cn&edition=full","pubTime":"2025-09-22 14:07","pubTimestamp":1758521220,"startTime":"0","endTime":"0","summary":"近期,百奥赛图在全球创新药产业链上的存在感愈发强烈。进入9月,公司接连发布三项合作消息,涵盖核酸药物递送、ADC研发与双抗ADC合作项目进展,充分展现了其“双业务线”战略的纵深布局与国际竞争力。这一项目代表了百奥赛图在双抗ADC领域的技术实力,也凸显了其在国际合作中的重要地位。在创新药产业进入组合化、精准化的趋势下,百奥赛图通过“双业务线”逻辑已成功实现从传统CRO到创新型平台企业的跨越。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092214071897a1b282&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092214071897a1b282&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":1},{"id":"2569753418","title":"百奥赛图IPO:一面是A+H“光辉”,一面是大量人员“优化”,扭亏为盈的背后,心酸的“研发耗材”","url":"https://stock-news.laohu8.com/highlight/detail?id=2569753418","media":"中金在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569753418?lang=zh_cn&edition=full","pubTime":"2025-09-22 10:41","pubTimestamp":1758508887,"startTime":"0","endTime":"0","summary":"以上是基于现有招股说明书整理了百奥赛图的员工情况,从24年中间数来看,2024年,管理人员变动20%,研发人员变动率起码超过50%……2300万的辞退代价,换8600万的利润增量,还能实现“扭亏为盈”的里程碑意义,拥有一份好看的报表,和可以“畅想的未来”,确实是赚的","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922105108a43b5277&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922105108a43b5277&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2568885257","title":"百奥赛图-B09月19日主力净流出0.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2568885257","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568885257?lang=zh_cn&edition=full","pubTime":"2025-09-19 16:16","pubTimestamp":1758269760,"startTime":"0","endTime":"0","summary":"09月19日, 百奥赛图-B股价跌0.15%,报收27.50元,成交金额1255.2万元,换手率0.42%,振幅4.94%,量比0.55。百奥赛图-B今日主力资金净流出0.7万元,上一交易日主力净流入42.8万元。该股近5个交易日上涨21.74%,主力资金累计净流出73.7万元;近20日主力资金累计净流出112.6万元,其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919162417979cd785&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919162417979cd785&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","BK1161"],"gpt_icon":0},{"id":"2568925200","title":"百奥赛图合作伙伴IDEAYA举办十周年研发日,携手推进双抗ADC联合治疗新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2568925200","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568925200?lang=zh_cn&edition=full","pubTime":"2025-09-19 15:39","pubTimestamp":1758267540,"startTime":"0","endTime":"0","summary":"百奥赛图祝贺合作伙伴IDEAYA Biosciences的十周年研发日在9月8日圆满举行。IDEAYA在会上公布了多项研发进展,其中重点提及了双方合作的B7-H3/PTK7双特异性抗体偶联药物IDE034。IDEAYA预计将在2025年第四季度完成IND申报,预期适应症覆盖肺癌、结直肠癌、头颈鳞癌及卵巢癌患者群体。百奥赛图在双抗ADC研发领域拥有领先优势。随着全球研发趋势逐步迈向多元化与组合化,ADC与小分子药物的联合治疗正日益成为重要方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919153930a436a446&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919153930a436a446&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02315"],"gpt_icon":0},{"id":"2568887257","title":"基本面没变,港股混得不咋地的百奥赛图,能混好A股吗?尽管巨亏32.5亿以上,沈月雷2024年年薪42","url":"https://stock-news.laohu8.com/highlight/detail?id=2568887257","media":"中金在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568887257?lang=zh_cn&edition=full","pubTime":"2025-09-19 14:26","pubTimestamp":1758263190,"startTime":"0","endTime":"0","summary":"曾经在港股跌得鼻青脸肿的百奥赛图,如今又要来科创板“吸金”了。9月24日,百奥赛图将迎来科创板上会审议的关键时刻。如今,在港股混得不咋地的百奥赛图,带着几乎同样的基本面转战A股,能混出个名堂吗?根据招股书数据,2021年至2024年,百奥赛图实现营收分别为3.55亿元、5.34亿元、7.17亿元和9.81亿元。更令人担忧的是,研发团队规模从2022年底的627人锐减至2024年6月底的288人,降幅达54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919144035a4368a5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919144035a4368a5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","HSCEI","BK1161","02315"],"gpt_icon":1},{"id":"2568252045","title":"百奥赛图IPO:公司基本信息速览","url":"https://stock-news.laohu8.com/highlight/detail?id=2568252045","media":"览富财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568252045?lang=zh_cn&edition=full","pubTime":"2025-09-19 14:08","pubTimestamp":1758262103,"startTime":"0","endTime":"0","summary":"百奥赛图将于9月24日接受上交所上市委审核。百奥赛图(北京)医药科技股份有限公司是一家创新药临床前CRO及生物技术公司。此外,百奥常青、百奥常盛、祐和常青、祐和常盛为发行人股权激励平台,截至本招股说明书签署日,合计持有发行人13.1584%股份。该《一致行动协议》在任何一方持有百奥赛图股权期间持续有效。综上,截至招股说明书签署日,沈月雷、倪健合计直接或间接控制发行人 27.0291% 表决权,为百奥赛图共同控股股东、实际控制人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919140840979c97ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919140840979c97ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","02315"],"gpt_icon":0},{"id":"1156906272","title":"生物医药B类股午后拉升,百奥赛图涨超11%,润迈德涨超8%,加科思涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156906272","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156906272?lang=zh_cn&edition=full","pubTime":"2025-09-18 13:27","pubTimestamp":1758173248,"startTime":"0","endTime":"0","summary":"9月18日(周四),港股$生物(000504)$医药B类股午后拉升,$百奥赛图(02315)$涨超11%,润迈德涨超8%,$加科思(01167)$涨超5%,$开拓药业(09939)$涨超5%,和誉、创胜集团、三叶草生物涨超4%","market":"us","thumbnail":"https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3f74022f06933621fba8da03310c7780","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315","BK1100","150131","02297"],"gpt_icon":0},{"id":"2568472224","title":"百奥赛图(02315)技术平台频结硕果 连签默克、Tubulis等推进国际化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2568472224","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568472224?lang=zh_cn&edition=full","pubTime":"2025-09-18 11:36","pubTimestamp":1758166563,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,近日,百奥赛图公布与默克、Tubulis、IDEAYA的多项合作及研发进展引起市场关注,凸显其在抗体药物研发及创新递送技术领域的平台实力与国际合作成效。此外,百奥赛图近期宣布先后与德国Tubulis及全球领先的科技公司默克达成合作协议。Tubulis拟引进百奥赛图自主开发的全人抗体推进其ADC产品的研发和商业化。百奥赛图将获得一笔首付款,还将有权获得开发、监管及商业化里程碑付款以及个位数净销售额分成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1c2e6bc5fe5e88020e64b175354f9941","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2361044949.HKD","BK4588","LU1430594728.SGD","LU2089984988.USD","LU0106261372.USD","IE00B4R5TH58.HKD","LU0861579265.USD","LU1069347547.HKD","LU1989771016.USD","LU2361044865.SGD","IE00BLSP4452.SGD","LU1162221912.USD","LU1093756325.SGD","LU1093756168.USD","IE0009355771.USD","SG9999014559.SGD","IE000M9KFDE8.USD","LU0266013472.USD","SG9999013999.USD","LU0098860793.USD","LU0289739699.SGD","LU1023059063.AUD","LU1035773651.USD","MRK","LU0211331839.USD","LU1699723380.USD","SG9999002232.USD","LU1571399168.USD","LU1116320901.HKD","IE00BLSP4239.USD","LU0265550946.USD","LU1989772923.USD","LU2023250843.SGD","LU1974910355.USD","SG9999002224.SGD","LU0965509101.SGD","LU0234572021.USD","LU1116320737.USD","LU0070302665.USD","02315","LU1585245621.USD","SG9999001176.USD","LU0203347892.USD","LU1061106388.HKD","LU1066051498.USD","SG9999001440.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU1929549753.HKD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2568444695","title":"港股异动 | 百奥赛图涨超10%,科创版IPO即将接受审议,月初与默克达成抗体授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2568444695","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568444695?lang=zh_cn&edition=full","pubTime":"2025-09-18 10:01","pubTimestamp":1758160893,"startTime":"0","endTime":"0","summary":"9月18日(周四),$百奥赛图-B$涨超10%,截至发稿,涨10.12%,报27.42港元,成交额1316万港元。消息面上,9月17日,上交所上市审核委员会发布公告,百奥赛图的科创板IPO迎来关键节点,首发事项将于9月24日接受审议。根据协议条款,百奥赛图将提供基于其RenMice平台自主开发的全人抗体,由默克评估将其用于抗体偶联LNP制剂服务的可行性。默克被授予获取选中抗体资产权益的独家选择权,百奥赛图有权获得相应的费用付款及销售分成和再许可分成。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1c2e6bc5fe5e88020e64b175354f9941","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346617.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["YANG","159982","IE000M9KFDE8.USD","LU1069347547.HKD","MRK","LU1571399168.USD","BK1161","IE00BJJMRZ35.SGD","HSCEI","SG9999001176.SGD","LU1037948541.HKD","LU0058720904.USD","SG9999002232.USD","LU1974910355.USD","IE0009355771.USD","LU2089984988.USD","LU0098860793.USD","BK4559","LU1989772840.SGD","02315","LU1983299246.USD","SG9999002224.SGD","LU1941712348.USD","LU0211331839.USD","LU0965509010.AUD","LU1061106388.HKD","LU1989772923.USD","SGXZ57979304.SGD","LU0070302665.USD","LU1116320737.USD","LU2361044949.HKD","BK4007","IE00BFTCPJ56.SGD","LU0238689110.USD","SG9999014542.SGD","LU0861579265.USD","IE00BJT1NW94.SGD","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU1035773651.USD","LU1057294990.SGD","LU1037948897.HKD","LU2023250504.SGD","LU1699723380.USD","IE00BN8TJ469.HKD","LU0266013472.USD","BK4614","LU1989771016.USD","LU0965509283.SGD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.bbctg.com.cn","stockEarnings":[{"period":"1week","weight":-0.0873},{"period":"1month","weight":-0.0279},{"period":"3month","weight":0.1858},{"period":"6month","weight":1.0423},{"period":"1year","weight":2.3619},{"period":"ytd","weight":1.9506}],"compareEarnings":[{"period":"1week","weight":-0.0313},{"period":"1month","weight":0.0034},{"period":"3month","weight":0.0891},{"period":"6month","weight":0.257},{"period":"1year","weight":0.2371},{"period":"ytd","weight":0.3106}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司通过五个分部开展业务。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动物。抗体开发分部利用抗体发现平台识别有可能成为候选药物的抗体。创新药开发分部研发创新药,专注肿瘤学和自身免疫性疾病治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.105956},{"month":2,"riseRate":0.666667,"avgChangeRate":0.052338},{"month":3,"riseRate":0.333333,"avgChangeRate":0.185414},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.066586},{"month":5,"riseRate":0.666667,"avgChangeRate":0.14952},{"month":6,"riseRate":0.333333,"avgChangeRate":0.011218},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.033427},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.055975},{"month":9,"riseRate":0.666667,"avgChangeRate":0.092895},{"month":10,"riseRate":0.25,"avgChangeRate":-0.122115},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.03316},{"month":12,"riseRate":0.333333,"avgChangeRate":0.146863}],"exchange":"SEHK","name":"百奥赛图-B","nameEN":"BIOCYTOGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥赛图-B(02315)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥赛图-B(02315)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥赛图-B,02315,百奥赛图-B股票,百奥赛图-B股票老虎,百奥赛图-B股票老虎国际,百奥赛图-B行情,百奥赛图-B股票行情,百奥赛图-B股价,百奥赛图-B股市,百奥赛图-B股票价格,百奥赛图-B股票交易,百奥赛图-B股票购买,百奥赛图-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥赛图-B(02315)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥赛图-B(02315)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}